INTRODUCTION {#sec0005}
============

The term hippocampal sclerosis (HS) \[[@ref001]\] is commonly used to refer to old age-associated brain disease with neuronal loss and gliosis in the hippocampal formation that is out of proportion to AD-type pathology \[[@ref012]\] and often associated with TDP-43 (Transactive response binding protein-43) pathology \[[@ref018]\]. Typical clinical presentation shows cognitive and functional impairment \[[@ref007]\], and HS can be difficult to distinguish, especially from late-onset Alzheimer's disease (AD) \[[@ref001]\]. Frequently, HS occurs with other age-related neurodegenerative pathologies, and it occurs only rarely without any comorbid pathology \[[@ref023]\]. Definitions of HS have traditionally varied \[[@ref020]\], which complicates comparison of HS studies.

The reported prevalence of HS in aged populations is variable, ranging from 2.8% to over 20% \[[@ref004]\]. A recent meta-analysis, largely confined to hospital-based materials, reported the oldest old to have a peak in incidence of HS after the age of 95 years \[[@ref007]\]. However, there are only few population/community-based studies \[[@ref020]\] where the prevalence of HS can be reliably investigated. Furthermore, only few studies have systematically investigated whether the loss of neurons appears bilaterally or unilaterally \[[@ref011]\].

In this study we sought to address the following questions: 1) The prevalence of HS in our unique population based study material (Vantaa 85+ study, all the individuals aged 85 years or over); 2) The frequency of uni- versus bilateral HS; 3) The frequency of HS subjects without any comorbid pathology (absence of apparent other neurodegenerative or vascular disease); 4) The association of HS with other neurodegenerative and vascular pathologies; 5) The associations of TDP-43 and HPtau (hyperphosphorylated)-positive pathology with HS.

MATERIAL AND METHODS {#sec0010}
====================

Subjects and clinical examination {#sec0015}
---------------------------------

The Vantaa 85+ study includes all individuals aged ≥85 years, who were living in the city of Vantaa (Southern Finland) as of 1 April 1991 (N = 601). Clinical examination was possible in 553 subjects, and autopsies were carried out in 302/553 subjects (55%). Informed consent for the study was requested from the individuals and/or their close relatives. The approval for the study was admitted by the Ethics Committee of Health Center City of Vantaa. Handling of the health and social work data as well the death certificates was approved by the Finnish Health and Social Ministry. The National Authority for Medico Legal Affairs (VALVIRA) accepted the autopsy tissue sample collection and usage for research purposes. Dementia was diagnosed as part of the clinical examination according to the DSMIIIR criteria. The clinical examinations were performed in 1991, 1994, 1996, 1999, and 2001.

Tissue samples {#sec0020}
--------------

Originally, for the previously reported study on AD \[[@ref044]\], hippocampal samples were obtained after at least two weeks formalin-fixation from the right cerebral hemisphere at the level of the lateral geniculate body, and embedded in polyethylene glycol (PEG). Those tissue blocks were re-processed to paraffin for this study. First, a vast majority of PEG matrix was removed manually, after that the blocks were immersed for 2 min in distilled water. The blocks were kept in neutral buffered formalin O/N at room temperature to make sure that PEG was totally removed. Finally, the blocks were processed in tissue processor (Thermo Shandon Excelsior, Thermo Fisher, USA), and embedded into paraffin.

For bilateral assessment of the hippocampal pathology, also the left hippocampus was sampled after several years of formalin-fixation, and embedded in paraffin. The bilateral tissue sections of 6μm, stained for standard HE, were used for estimation of general histopathological findings and stage of neuronal loss in each field of the hippocampus. Our standard sampling and assessment protocols to define pathologies related to AD, Lewy body disease, macroscopic brain infarcts and cerebral amyloid angiopathy have been described previously \[[@ref041]\]. Braak staging of neurofibrillary degeneration was based on Gallyas stained slides as reported before \[[@ref044]\]. Assessment of Lewy body pathology was based on immunopositivity of Lewy bodies and neurites (α-synuclein, clone 42, Transduction Laboratories, USA) as described previously \[[@ref043]\]. The assessment of vascular pathology \[[@ref042]\] and a standardized neuropathology protocol for neuritic plaque score, CERAD \[[@ref044]\], has been reported previously. The diagnosis of capillary amyloid-β was determined using Congo red and confirmed by amyloid-β immunohistochemistry (amyloid-β, clone 4G, Senetek PLC, USA) as described earlier \[[@ref041]\].

Defining histopathological alterations and laterality {#sec0025}
-----------------------------------------------------

HS and hemispheric symmetry/asymmetry was determined on HE-staining by estimating the severity of neuronal loss. The density of neurons was assessed semi-quantitatively by three observers MK, LM and AP using a multi-viewer microscope. The criterion for HS was based on discussions of the observers and the earlier publication of Rauramaa et al. \[[@ref025]\]. The extent of neuronal loss was categorized into three subdivisions.I.Intact/Infrequent; no sign or minor loss of pyramidal neurons in the CA1 and subiculumII.Frequent; severe marked loss of pyramidal neurons in the CA1 and subiculumIII.Complete; total loss of pyramidal neurons in the CA1 and subiculum

The subjects fulfilling the criteria for the subdivision I were included in the non-HS group in the statistical analyses.

The subjects fulfilling the criteria for the subdivisions II and III were included in the HS group in the statistical analyses.

Immunohistochemistry {#sec0030}
--------------------

The right sided hippocampus tissue blocks were cut into 4μm thick sections and stained with the immunostainer LabVision. For the antibodies (p62 \[[@ref045]\], TDP-43, and HPtau) we had to use stronger pretreatment conditions, prolonged incubations times and more sensitive detection kits compared to routine samples, due to the high age of the PEG-embedded tissues. The intense pretreatments and staining conditions caused artefactual staining of lipofuscin in some of the samples. However, the intensity and color of lipofuscin pigment (yellowish) was easily separated from the specific immunopositivity (dark brown) ([Fig. 1](#jad-63-jad171068-g001){ref-type="fig"}). The polymer- based detection kits were used for detection. All the immunoreactions were visualized using DAB. More detailed information on immunohistochemical stainings is presented in [Table 1](#jad-63-jad171068-t001){ref-type="table"}. The presence of any specific TDP-43, p62, and HPtau immunopositivity was noted in granular cell layer and in pyramidal cell sectors CA4, CA3, CA2, CA1, and subiculum. The results were ascertained in consensus sessions by three observers (MK, LM, and AP). We used p62- IHC- staining as a confirmatory staining, in order to replicate true neuropathological findings, such as TDP-43 positivity and, on the other hand, to identify other accompanying pathology.

![A) Hippocampal sclerosis, severe neuronal loss in CA1 sector, HE- stained. B) TDP-43 immunostaining of dentate fascia granule cells showing NCIs, (open arrow head), dark brown. Lipofuscin (star) is seen as yellowish granular deposits.](jad-63-jad171068-g001){#jad-63-jad171068-g001}

###### 

Immunohistochemistry procedures in this study

  Antibody     Clone, Catalog number, Manufacturer
  ------------ ---------------------------------------
  TDP-43^\*^   11-9, CAC-TIP-PTD-M01, Cosmobio Japan
  PHTau^\*^    AT8, 90206, Innogenetics, Belgium
  p62^\*^      D-3, sc-28359 Santa Cruz, USA

^\*^General steps for all used antibodies during IHC- staining: 1. Endogenous peroxidase activity was blocked by REAL^TM^ Peroxidase-Blocking Solution (Dako, S2023, Glostrup, Denmark). 2. Immunoreactions were visualised with DAB (3, 3\'-diaminobenzidine tetra- hydrochloride) (Dako, K5007, Agilent, USA). 3. Counterstaining (Mayer\'s hematoxylin, S330930-2, Agilent, USA) was performed with slide staining instrument SAKURA TISSUE-TEK^®^ PRISMA (Sakura Finetek Europe B.V., The Netherlands).

Statistical analyses {#sec0035}
--------------------

Statistical analyses ([Tables 2](#jad-63-jad171068-t002){ref-type="table"} and [3](#jad-63-jad171068-t003){ref-type="table"}) were performed using IBM SPSS Statistics version 22.0. The Chi-Square test was used to compare the differences of sex in individuals with and without HS, and with and without TDP-43 granular cell layer positivity. The Mann-Whitney U test was used to compare age at death in these groups. All the other analyses were performed using binary logistic regression, adjusted for age at death and sex.

###### 

Description of all study subjects, and subjects with and without hippocampal sclerosis. Results of association analyses with different variables

  Variable                                                      All study subjects        Non-Hippocampal sclerosis subjects   Hippocampal sclerosis subjects               *p*-value
  ------------------------------------------------------- ------------------------------ ------------------------------------ -------------------------------- -----------------------------------
  **Number of subjects**                                               302                               255                                 47                
  Sex                                                                                                                                                          
    Female/Male                                            250 (**82.8**)/52 (**17.2**)      208 (**81.6**)/47 (**18.4**)        42 (**89.4**)/5 (**10.6**)                    NS
  Age at death                                                                                                                                                 
    Mean                                                              92.35                             92.18                              93.22                               NS
    Range                                                         85.12--105.64                     85.52--105.64                      85.12--104.77           
  Dementia status                                                                                                                                              
    Demented/non-demented                                  195 (**64.6**)/107(**35.4**)     150 (**58.8**)/105 (**41.2**)        45 (**95.7**)/2 (**4.3**)                 \<0.001^\*^
    Demented: Female/Male                                  165 (**84.6**)/30(**15.4**)       124 (**82.7**)/26 (**17.3**)         41 (**91.1**)/4(**8.9**)                     NS
  CERAD                                                                                                                                                          **0.01**\< *p* ≤ **0.05**^\*\*^
    None                                                          71 (**23.5**)                     65 (**25.5**)                       6 (**12.8**)           
    Sparse                                                        33 (**10.9**)                     27 (**10.6**)                       6 (**12.8**)           
    Moderate                                                      160 (**53.0**)                    136 (**53.3**)                     24 (**51.1**)           
    Frequent                                                      38 (**12.6**)                     27 (**10.6**)                      11 (**23.4**)           
  BRAAK                                                                                                                                                                        NS
    0-II                                                          89 (**29.5**)                     73 (**28.7**)                      16 (**34.0**)           
    III-IV                                                        141 (**46.7**)                    125 (**49.0**)                     16 (**34.0**)           
    V-VI                                                          72 (**23.9**)                     57 (**22.6**)                      15 (**31.9**)           
  α- synuclein                                                                                                                                                                 NS
    None                                                          193 (**63.9**)                    165 (**64.7**)                     28 (**59.6**)           
    Brain Stem                                                     8 (**2.6**)                       5 (**2.0**)                        3 (**6.4**)            
    Limbic                                                        54 (**17.9**)                     48 (**18.8**)                       6 (**12.8**)           
    Neocortical                                                   47 (**15.6**)                     37 (**14.5**)                      10 (**21.3**)           
  Infarct (location)                                                                                                                                           
    Any                                                           162 (**53.6**)                    132 (**51.8**)                     30 (**63.8**)                           NS
    Heart                                                         119 (**41.2**)                    95 (**38.8**)                      24 (**54.5**)            **0.01\< p** **≤** **0.05**^\*\*^
    Small cortical                                                57 (**18.8**)                     46 (**18.1**)                      11 (**23.4**)                           NS
    Large cortical                                                51 (**16.9**)                     46 (**18.0**)                       5 (**10.6**)                           NS
    Small white matter                                            44 (**14.6**)                     34 (**13.4**)                      10 (**21.4**)                           NS
    Large white matter                                             6 (**2.0**)                       6 (**2.4**)                         0 (**0**)                             NS
    Small basal ganglia                                           60 (**19.8**)                     49 (**19.2**)                      11 (**23.4**)                           NS
    Large basal ganglia                                            1 (**0.3**)                       1 (**0.4**)                         0 (**0**)                             NS
    Small brain stem                                               13 (**4.3**)                      8 (**3.1**)                        5 (**10.6**)                           NA
    Large brain stem                                                (**0.3**)1                       1 (**0.4**)                         0 (**0**)                             NS
    Small cerebellum                                              53 (**17.6**)                     43 (**16.9**)                      10 (**21.2**)                           NS
    Large cerebellum                                               15 (**4.9**)                      12 (**4.7**)                       3 (**6.4**)                            NS
    Anterior circulation                                          121 (**40.1**)                    100 (**39.2**)                     21 (**44.7**)                           NS
    Posterior circulation                                         98 (**32.5**)                     77 (**30.2**)                      21 (**44.7**)                           NS
  Other vascular variables                                                                                                                                     
    Cerebral amyloid angiopathy (all six brain regions)           103(**34.1**)                      91(**35.7**)                       12(**25.5**)                           NS
    Atherosclerosis in the circle of Willis                       271 (**90.0**)                    223 (**95.3**)                      48 (**100**)                           NS
    Coronary disease                                              289 (**95.7**)                    245 (**96.1**)                     44 (**93.6**)                           NS
  Immunopositivity                                                                                                                                             
    TDP-43                                                                                                                                                     
    CA4                                                            1 (**0.4**)                       3 (**6.4**)                        4 (**1.3**)                            NA
    CA3-CA2                                                        3 (**1.0**)                       1 (**0.4**)                        2 (**4.3**)                            NA
    CA1 + Subiculum                                               98 (**32.5**)                     63 (**24.7**)                      35 (**74.5**)                       \<0.001^\*^
    GCL                                                           68 (**22.5**)                     33 (**12.9**)                      35 (**74.5**)                       \<0.001^\*^
    p62                                                                                                                                                        
    CA4-CA1-Subiculum                                             173 (**57.7**)                    144 (**56.9**)                     29 (**61.7**)                           NS
    GCL                                                           99 (**33.0**)                     62 (**24.5**)                      37 (**78.7**)                       \<0.001^\*^
    Tau                                                                                                                                                        
    CA4-CA1-Subiculum                                             274 (**91.3**)                    229 (**90.5**)                     45 (**95.7**)                           NS
    GCL                                                           167 (**55.7**)                    125 (**49.4**)                     42 (**89.4**)                       \<0.001^\*^

NS, no statistical significance. NA, not applicable, N too low for descriptive statistical analysis. ^\*^*p*- values \<0.001, strong statistical significance. ^\*\*^0.01 \< *p*≤0.05, weak statistical significance. ^rmbox*i*^A standardized neuropathology protocol for neuritic plaque score developed by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) \[[@ref014]\]. ^rmbox*ii*^Criteria utilized, previously published \[[@ref012]\], a staging scheme for neurofibrillary tangles (NFTs) described by Braak and Braak which encloses six stages: no NFTs, Braak stages I/II with NFTs predominantly in entorhinal cortex and closely related areas, stages III/IV with NFTs more abundant in hippocampus and amygdala while extending slightly into association cortex, and stages V/VI with NFTs widely distributed throughout the neocortex and also involving primary motor and sensory areas. ^rmbox*iii*^The third CDLB guidelines for diagnosis of Lewy- body Dementia with modified criteria. The load of Lewy- related pathology (LRP) was semiquantitatively scored mild, moderate, severe and very severe and followed by the assignment of the type of LRP (none, brainstem- predominant, limbic and diffuse neocortical), \[[@ref043]\]. ^rmbox*iv*^The diagnosis of capillary amyloid-β was determined using Congo red and confirmed by Aβ immunohistochemistry, both analyzed in six brain areas. The severity of capillary Aβ was graded semi-quantitatively, and the severity of CAA was based on the percentage of affected vessels \[[@ref041]\]. ^rmbox*v*^The arteries of circulus Willis were inspected and opened at autopsy, and the degree of atherosclerosis was estimated based upon severity of obstruction in artery. The classification was subdivided into four categories: none, mild, moderate and severe. ^rmbox*vi*^Left anterior descending, left circumflex and right coronary arteries were dissected at autopsy. The degree of coronary atherosclerosis was estimated by the pathologist, and scored into four categories: none, mild, moderate and severe \[[@ref042]\]. ^rmbox*vii*^The presence of TDP-43 immunoreactivity were assessed in the regions CA1 and subiculum, CA2, CA3-CA4 and granular layer of dentate gyrus. TDP-43 immunoreactivity was determined as positive when NCIs seen in the granular cell layer and CA1 + subiculum. ^rmbox*viii*^p62 immunoreactivity was scored as positive if seen positive NCIs in the granular cell layer of the dentate gyrus \[[@ref045]\]. ^rmbox*ix*^Tau immunoreactivity was recorded mainly as neurofibrillary lesions and neuropil threads in the granular cell layer of the dentate gyrus, sectors CA1-CA4 and subiculum.

###### 

TDP-43 immunopositivity in the granular cell layer. Results of association analyses with different variables

  Variable                                             All study subjects        TDP-43GCL-immunonegative subjects   TDP-43GCL-immunopositive subjects                   *p*-value
  ---------------------------------------------- ------------------------------ ----------------------------------- ----------------------------------- -------------------------------------------
  **Number of subjects**                                      302                               234                                 68                  
  Gender                                                                                                                                                
    Female/Male                                   250 (**82.8**)/52(**17.2**)       191**(81.6)/**43**(18.4)**             59 (86.8)/9**(13.2)**                            NS
  Age at death                                                                                                                                          
    Mean                                                     92.35                             92.09                               93.23                  **0.01 \<** p **≤** **0.05^** \*\***^**
    Range                                                 85.12-105.64                     85.12-105.64                        86.61-103.02             
  Dementia status                                                                                                                                       
    Demented/non-demented                         195 (**64.6**)/107(**35.4**)     135 **(57. 7)/**99**(42.3)**          60 **(88.2)**/8**(11.8)**                  **\<0.001^**\***^**
    Demented: Female/Male                          165(**84.6**)/30(**15.4**)        112 **(83) /**23**(17)**            53 **(88.3)/**7**(11.7)**                          NS
  CERAD^i^                                                                                                                                                            **\<0.001**^\*^
    None                                                 71 (**23.5**)                     64 **(27.4)**                       7 **(10.3)**             
    Sparse                                               33 (**10.9**)                     26**(11.1)**                        7 **(10.3)**             
    Moderate                                             160 (**53.0**)                    124**(53.0)**                       36**(52.9)**             
    Frequent                                              38(**12.6**)                      20**(8.5)**                        18**(26.5)**             
  BRAAK^ii^                                                                                                                                              **0.01 \< *p*** **≤** **0.05^** \*\***^**
    0-II                                                 89 (**29.5**)                     71 **(30.3)**                       18 **(26.5)**            
    III-IV                                               141 (**46.7**)                   115 **(49.1)**                       26 **(38.2)**            
    V-VI                                                 72 (**23.8**)                     48 **(20.5)**                       24 **(35.3)**            
  α- synuclein^iii^                                                                                                                                       **0.01 \<** p **≤** **0.05^** \*\***^**
    None                                                 193 (**63.9**)                   155 **(66.2)**                       38 **(55.9)**            
    Brain Stem                                            8 (**2.6**)                       5 **(2.1)**                         3 **(4.4)**             
    Limbic                                               54 (**17.9**)                     44 **(18.8)**                       10 **(14.7)**            
    Neocortical                                          47 **(15.6**)                     30 **(12.8)**                       17 **(25.0)**            
  Infarct (location)                                                                                                                                    
    Non-selected                                         162 **(53.6)**                   121 **(51.7)**                       41 **(60.3)**                                NS
    Heart                                                119 **(41.2)**                    92 **(40.7)**                       27 **(42.9)**                                NS
    Small cortical                                       57 **(18.9)**                     42 **(17.9)**                       15 **(22.1)**                                NS
    Large cortical                                       51 **(16.9)**                     45 **(19.2)**                        6 **(8.8)**                                 NS
    Small white matter                                   44 **(14.7)**                     34 **(14.5)**                       10 **(14.7)**                                NS
    Large white matter                                    6 **(2.0)**                       4 **(1.7)**                         2 **(2.9)**                                 NS
    Small basal ganglia                                  60 **(19.8)**                     44 **(18.8)**                       16 **(23.5)**                                NS
    Large basal ganglia                                   1 **(0.3)**                        0 **(0)**                          1 **(1.5)**                                 NS
    Small brain stem                                      13 **(4.3)**                      9 **(3.8)**                         4 **(5.9)**                                 NS
    Large brain stem                                      1 **(0.3)**                       1 **(0.4)**                          0 **(0)**                                  NS
    Small cerebellum                                     53 **(17.5)**                     38 **(16.2)**                       15 **(22.1)**                                NS
    Large cerebellum                                      15 **(5.0)**                     11 **(4.7)**                         4 **(5.9)**                                 NS
    Anterior circulation                                 121 **(40.0)**                    93 **(39.7)**                       28 **(41.2)**                                NS
    Posterior circulation                                98 **(32.5)**                     69 **(29.5)**                       29 **(42.6)**              **0.01 \<** p **≤** **0.05^** \*\***^**
  Other vascular variables                                                                                                                              
    Cerebral amyloid angiopathy                          199**(65.9)**                     148**(63.2)**                       51**(68.0)**                                 NS
    (all six brain regions) ^iv^                                                                                                                        
    Atherosclerosis in the circle of Willis^v^           271 **(90.0)**                   211 **(95.5)**                       60 **(98.4)**                                NS
    Coronary disease^vi^                                 232 **(80.3)**                   178 **(78.8)**                       54 **(85.7)**                                NS
  Immunopositivity                                                                                                                                      
    p62^viii^                                                                                                                                           
    CA4-CA1-Subiculum                                    173 **(57.7)**                   134 **(57.5)**                       39 **(58.2)**                                NS
    GCL                                                  99 **(33.0)**                     43 **(18.5)**                       56 **(83.6)**                          **\<0.001**^\*^
    Tau^ix^                                                                                                                                             
    CA4-CA1-Subiculum                                    274 **(91.3)**                   211 **(47.6)**                       63 **(94.0)**                                NS
    GCL                                                  167 **(55.7)**                   111 **(47.6)**                       56 **(83.6)**                          **\<0.001**^\*^

NS, no statistical significance. NA, not applicable, N too low for descriptive statistical analysis. ^\*^*p*- values \< 0.001, strong statistical significance. ^\*\*^0.01 \< *p*≤0.05, weak statistical significance. ^i^A standardized neuropathology protocol for neuritic plaque score developed by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) \[[@ref014]\]. ^ii^Criteria utilized, previously published \[[@ref012]\], a staging scheme for neurofibrillary tangles (NFTs) described by Braak and Braak which encloses six stages: no NFTs, Braak stages I/II with NFTs predominantly in entorhinal cortex and closely related areas, stages III/IV with NFTs more abundant in hippocampus and amygdala while extending slightly into association cortex, and stages V/VI with NFTs widely distributed throughout the neocortex and also involving primary motor and sensory areas. ^iii^The third CDLB guidelines for diagnosis of Lewy-body Dementia with modified criteria. The load of Lewy-related pathology (LRP) was semiquantitatively scored mild, moderate, severe and very severe and followed by the assignment of the type of LRP (none, brainstem- predominant, limbic and diffuse neocortical), \[[@ref043]\]. ^iv^The diagnosis of capillary amyloid-β was determined using Congo red and confirmed by Aβ immunohistochemistry, both analyzed in six brain areas. The severity of capillary Aβ was graded semi-quantitatively, and the severity of CAA was based on the percentage of affected vessels \[[@ref041]\]. ^v^The arteries of circulus Willis were inspected and opened at autopsy, and the degree of atherosclerosis was estimated based upon severity of obstruction in artery. The classification was subdivided into four categories: none, mild, moderate and severe. ^vi^Left anterior descending, left circumflex and right coronary arteries were dissected at autopsy. The degree of coronary atherosclerosis was estimated by the pathologist, and scored into four categories: none, mild, moderate and severe \[[@ref042]\]. ^vii^The presence of TDP-43 immunoreactivity were assessed in the regions CA1 and subiculum, CA2, CA3-CA4 and granular layer of dentate gyrus. TDP-43 immunoreactivity was determined as positive when NCIs were seen in the granular cell layer and CA1 + subiculum. ^viii^p62 immunoreactivity was scored as positive if seen positive NCIs in the granular cell layer of the dentate gyrus \[[@ref045]\]. ^ix^Tau immunoreactivity was recorded mainly as neurofibrillary lesions and neuropil threads in the granular cell layer of the dentate gyrus, sectors CA1-CA4 and subiculum.

RESULTS {#sec0040}
=======

Hippocampi of both hemispheres were analyzed in all subjects of this population-based cohort. 47 of 302 (15.6%) subjects had severe (subdivision II) or complete loss of neurons (subdivision III) of the CA1 sector and subiculum, defined as HS ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). There were 31 subjects in the subdivision II and 16 subjects in the subdivision III. Of those 47 subjects, bilateral changes were observed in 51.1%. Unilateral changes were seen in 23/47 subjects with HS, and unilateral changes were more common in the left than in the right hemisphere. On both sides, degree of neuronal loss in the CA1 sector was more severe compared to that in the subiculum (more severe changes in the CA1 sector were seen in 88% of the sections from the right side, and in 84% of the sections from the left side). Only one subject (1/47) was found to have HS without any other significant neurodegenerative pathology. This subject had severe bilateral neuronal loss in CA1 and subiculum and robust TDP-43 immunopositivity in the granular cell layer of the dentate fascia ([Fig. 1](#jad-63-jad171068-g001){ref-type="fig"}).

The majority of the subjects with HS were women (89.4%), but there was no statistical evidence for an association between HS and sex ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). Overall, the subjects with HS were older at the time of death (on average 12 months), even though this difference was not statistically significant (*p* \> 0.05) ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). 45 (95.7%) of the 47 subjects with HS were demented (*p* \< 0.001) ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). The CERAD score was weakly associated with HS (0.01\< *p*≤0.05), whereas neither Braak stage nor Lewy related pathology showed any association ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). When frequencies of infarcts in different locations were compared in subjects with and without HS, an association was seen with heart infarct, 0.01\< *p*≤0.05 ([Table 2](#jad-63-jad171068-t002){ref-type="table"}).

HS was strongly associated with TDP-43 positive neuronal cytoplasmic inclusions (NCI) in the granular cell layer of fascia dentate, *p* \< 0.001 ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). A strong association with TDP-43 positive findings in the sectors CA1 and subiculum was also found ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). In the CA1- sectors and subiculum, TDP-43 staining showed some neuronal cytoplasmic inclusions (NCI) and a few neuronal intranuclear inclusions (NII) (in residual neurons). In addition, short dystrophic neurites, neuropil threads, and rarely in some cases, faintly labelled neurofibrillary tangle- like changes were seen. There was variation in the frequencies found among the TDP-43 deposits in CA1 and subiculum in the HS samples. Tau pathology was recorded mainly as neurofibrillary lesions and neuropil threads. Interestingly, HPtau immunopositivity of the granular cell layer was strongly associated with HS, *p* \< 0.001 ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). Not surprisingly, the same applied to p62-positive NCI aggregates, *p* \< 0.001, ([Table 2](#jad-63-jad171068-t002){ref-type="table"}).

As the TDP-43 positivity in the granular cell layer of the hippocampus has been suggested to be an early marker of HS \[[@ref023]\], we also analyzed all the variables listed above comparing subjects with immunopositivity of TDP-43 in the granular cell layer and those without this kind of immunopositivity ([Table 3](#jad-63-jad171068-t003){ref-type="table"}). These analyses showed a strongly significant association (*p* \< 0.001) with dementia, CERAD score, p62 and HPtau positivity in granular cell layer. The following variables showed more modest association (0.01\< *p*≤0.05): age at death, Braak stage, α-synuclein pathology and infarcts in the area of posterior circulation.

DISCUSSION {#sec0045}
==========

In this population-based study on subjects \>85 years old, we found that 1) prevalence of HS was 16%, thus representing one of the most frequent neuropathologies in this age group. 2) Almost a half (49%) of subjects with HS showed unilateral disease. 3) Only 2% of subjects with HS did not show any other neurodegenerative pathology, suggesting that HS without any comorbid pathology is rare. 4) HS was strongly associated with dementia, immunopositivity for TDP-43 and HPtau in the granular cell layer of the fascia dentate in the hippocampus and modestly with AD-associated neuritic plaques (CERAD score) and vascular pathological variables, most notably heart infarcts.

According to the literature, 10--25% of individuals older than 85 manifest HS in autopsy samples \[[@ref004]\]. The frequency of 15.6% found in our study is in accordance with previous studies on this age group \[[@ref004]\]. Some of the earlier studies have reported lower frequencies, but these studies may have been influenced by their investigation of younger cohorts \[[@ref001]\]. It is noteworthy that the prevalence of HS has been shown to increase in the very elderly, particularly after 95 years \[[@ref007]\]. This age group was represented in our study, where the mean age at death for HS subjects was 93.22 years, and the oldest subject was 104.7 years old at the time of death. In addition, awareness of HS has considerably increased during the last ten years, which may have influenced the number of diagnoses of HS, and may have had an impact on the prevalence figures. Our study confirmed the strong association with HS and dementia (*p* \< 0,001) \[[@ref001]\]. Only 2 out of 47 subjects with HS were not demented ([Table 2](#jad-63-jad171068-t002){ref-type="table"}) and they both had unilateral HS.

Most of the studies have reported male predominance for HS \[[@ref011]\]. This is in contrast to our population-based study, as we found women with HS to be more prevalent ([Table 2](#jad-63-jad171068-t002){ref-type="table"}). The difference may reflect the fact that in our population-based sample of the very elderly, the great majority of study subjects were women, whereas most of the other studies have been based on younger populations and the proportion of males has been much greater. This was also the case in the previous community-based study, where the mean age at death was almost 10 years younger than in our study \[[@ref030]\].

HS without comorbid neurodegenerative pathology has been reported to occur in 0.4%--5.4% among the individuals with HS \[[@ref001]\]. We found only one (2.1%) such subject. In this study, HS without any significant comorbid pathology was defined according to the following criteria: Braak stage to be zero and the CERAD score to be one, no neurofibrillary tangles seen with HPtau antibody and no sign of Lewy related pathology with α-synuclein antibody. In the previously reported studies the definition for HS without any comorbid pathology has varied to some extent \[[@ref001]\] allowing generally more relaxed criteria.

The borderline between HS and other diseases, in particular AD, has been problematic. HS as part of aging pathology has been reported to be found in individuals with both low severity of AD and high severity of AD pathology \[[@ref035]\]. The prevalence of HS pathology has been shown to increase dramatically beyond the age 95, while the prevalence of AD- type pathology declines in that age group \[[@ref007]\]. These findings might suggest that HS and AD pathologies may occur independently from each other, even though they affect the same part of the hippocampus \[[@ref007]\]. In this study we found only a weak association between HS and CERAD neuritic plaque score, in accordance with previous studies, where the co-occurrence of HS pathology with variable CERAD neuritic plaque scores has been reported \[[@ref035]\]. More interestingly, we did not find any association with Braak stage, but HPtau-immunopositivity in the granular cell layer was associated with both HS and granular cell TDP-43 pathology. This is in agreement with a recent study, where dentate fascia granule cells NFTs were frequently found in HS cases, independent from Braak stage \[[@ref023]\].

Laterality of HS has been reported in a few published studies \[[@ref011]\]. In most studies hippocampus is sampled only from one hemisphere, which is a general approach in neuropathological practice, and thus it is possible that the reported frequencies for HS are underestimated. Here, we found 51.1% of HS cases to be bilateral. Similar frequencies have been seen in those few other studies, which have sampled hippocampi from both hemispheres \[[@ref011]\]. Importantly, it should be routine practice in neuropathological examination to sample both hippocampi, in order to be able to make a reliable diagnosis on demented subjects.

We found a strong association between HS and immunopositivity of TDP-43 in the granular cell layer of the fascia dentate, the CA1 and subiculum ([Table 2](#jad-63-jad171068-t002){ref-type="table"}), in accord with previous studies \[[@ref018]\]. In order to study, if TDP-43 positivity in the granular cell layer of could be an early marker of HS, as suggested recently \[[@ref023]\], we performed association analyses using two different dependent variables: 1) HS defined by the HE finding and 2) TDP43-positivity in the granular cell layer. We found very similar results in both analyzes, in accordance with the early marker hypothesis, even though TDP43-positivity in the granular cells was clearly not specific for HS. Recently, it has also been suggested that TDP-43 pathology in HS could be a secondary phenomenon reflecting pancerebral arteriolosclerosis \[[@ref023]\]. This finding certainly needs to be replicated by other studies. Although some vascular markers were weakly associated with HS and TDP-43 positivity in the granular cells in our material, we do not have data on brain arteriolosclerosis available in our dataset, and thus this hypothesis could not be assessed here.

There are several strengths and limitations in our study. The Vantaa 85+ study is prospective and population-based, and thus not influenced by selection bias, commonly affecting epidemiological studies. On the other hand, the study material is relative small in size, which may have resulted in lack of power in association analyses. Even though hippocampi from both sides were investigated, we were not able to study the possible segmentality of lesions \[[@ref046]\], as the hippocampi samples were collected only at the level of the lateral geniculate body. We managed to use the right side hippocampal PEG- embedded tissue blocks (being PEG-embedded for 14--24 years) for HE- and immunohistochemical stainings, after reprocessing of those blocks into FFPE- blocks, which are easier to handle. To the best of our knowledge, this procedure has not been reported before. This method could be useful for other research groups having historical PEG-embedded material. Authors' disclosures available online (<https://www.j-alz.com/manuscript-disclosures/17-1068r1>).
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